Developments of microfluidics for orthopedic applications: A review

Sun, Miao; Gong, Jiaxing; Cui, Wushi; Li, Congsun; Yu, Mengfei; Ye, Hua; Cui, Zhanfeng; Chen, Jing; He, Yong; Liu, An; Wang, Huiming

doi:10.1016/j.smaim.2022.07.001

Cited by 8 publications

(6 citation statements)

References 124 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Microfluidic devices exhibit channel dimensions within the range of 10-1,000 μm, enabling the control of small volumes of fluid. Microfluidic technology is highly advantageous in facilitating the development of physiological microenvironments characterized by 3D designs and precise functionalities at the microscale (Mansoorifar et al, 2021;Sun et al, 2023). Besides that, 3D metrics enable precise control of temporal and spatial parameters within cell culture.…”

Section: Oxygen-carrying Microfluidic Devicesmentioning

confidence: 99%

Oxygen generating biomaterials at the forefront of regenerative medicine: advances in bone regeneration

Zhao,

Zhou,

Xiao

et al. 2024

Front. Bioeng. Biotechnol.

View full text Add to dashboard Cite

Globally, an annual count of more than two million bone transplants is conducted, with conventional treatments, including metallic implants and bone grafts, exhibiting certain limitations. In recent years, there have been significant advancements in the field of bone regeneration. Oxygen tension regulates cellular behavior, which in turn affects tissue regeneration through metabolic programming. Biomaterials with oxygen release capabilities enhance therapeutic effectiveness and reduce tissue damage from hypoxia. However, precise control over oxygen release is a significant technical challenge, despite its potential to support cellular viability and differentiation. The matrices often used to repair large-size bone defects do not supply enough oxygen to the stem cells being used in the regeneration process. Hypoxia-induced necrosis primarily occurs in the central regions of large matrices due to inadequate provision of oxygen and nutrients by the surrounding vasculature of the host tissues. Oxygen generating biomaterials (OGBs) are becoming increasingly significant in enhancing our capacity to facilitate the bone regeneration, thereby addressing the challenges posed by hypoxia or inadequate vascularization. Herein, we discussed the key role of oxygen in bone regeneration, various oxygen source materials and their mechanism of oxygen release, the fabrication techniques employed for oxygen-releasing matrices, and novel emerging approaches for oxygen delivery that hold promise for their potential application in the field of bone regeneration.

show abstract

Section: Oxygen-carrying Microfluidic Devicesmentioning

confidence: 99%

Oxygen generating biomaterials at the forefront of regenerative medicine: advances in bone regeneration

Zhao,

Zhou,

Xiao

et al. 2024

Front. Bioeng. Biotechnol.

View full text Add to dashboard Cite

show abstract

“…Similar to OOC platforms, BOCs have been actively utilized in various biomedical applications, including bone-related basic mechanisms, disease models, drug discovery, and regenerative medicine. 4,6,10,17,21 In the following sections, many previous articles have been reviewed by categorizing the four fields: bone remodeling, disease modeling, tissue regeneration, and drug testing. 4.1.…”

Section: Recent Biomedical Applications Of Bocsmentioning

confidence: 99%

“…Microfluidic devices have channel dimensions ranging from 10 to 1000 μm in size and allow small amounts of fluid flow. Microfluidic technology is particularly helpful in providing physiological microenvironments with three-dimensional (3D) architectures and specific functions at the microscale. , Moreover, 3D metrics allow for fine control over spatial and temporal parameters in cell culture.…”

Section: Advantages Of Microfluidics For Boc Developmentmentioning

confidence: 99%

“…The BOC platform is useful for understanding complex biological processes in bone, identifying the role of each specific factor associated with the biological phenomena, and independently analyzing their impact. Similar to OOC platforms, BOCs have been actively utilized in various biomedical applications, including bone-related basic mechanisms, disease models, drug discovery, and regenerative medicine. ,,,, In the following sections, many previous articles have been reviewed by categorizing the four fields: bone remodeling, disease modeling, tissue regeneration, and drug testing.…”

Section: Recent Biomedical Applications Of Bocsmentioning

confidence: 99%

See 1 more Smart Citation

Bone-on-a-Chip: Biomimetic Models Based on Microfluidic Technologies for Biomedical Applications

Kim

Paek

Woo

et al. 2023

ACS Biomater. Sci. Eng.

View full text Add to dashboard Cite

With the increasing importance of preclinical evaluation of newly developed drugs or treatments, in vitro organ or disease models are necessary. Although various organ-specific on-chip (organ-on-a-chip, or OOC) systems have been developed as emerging in vitro models, bone-on-a-chip (BOC) systems that recapitulate the bone microenvironment have been less developed or reviewed compared with other OOCs. The bone is one of the most dynamic organs and undergoes continuous remodeling throughout its lifetime. The aging population is growing worldwide, and healthcare costs are rising rapidly. Since in vitro BOC models that recapitulate native bone niches and pathological features can be important for studying the underlying mechanism of orthopedic diseases and predicting drug responses in preclinical trials instead of in animals, the development of biomimetic BOCs with high efficiency and fidelity will be accelerated further. Here, we review recently engineered BOCs developed using various microfluidic technologies and investigate their use to model the bone microenvironment. We have also explored various biomimetic strategies based on biological, geometrical, and biomechanical cues for biomedical applications of BOCs. Finally, we addressed the limitations and challenging issues of current BOCs that should be overcome to obtain more acceptable BOCs in the biomedical and pharmaceutical industries.

show abstract

“…Rheumatoid arthritis (RA), a systemic multi-joint chronic inflammation with a high incidence worldwide, can eventually lead to joint deformity and destruction, which brings a heavy burden to individuals, families, and society. − The objective of clinical treatment of RA is to avoid joint disability, reduce inflammatory response, and alleviate systemic symptoms. − Generally, there are four major drugs including nonsteroidal anti-inflammatory drugs, glucocorticoids, disease-modifying anti-rheumatic drugs (DMARDs), and biologics. , Methotrexate (MTX), as a first-line small-molecule DMARD and a dihydrofolate reductase inhibitor, can inhibit the proliferation of macrophages and reduce the levels of inflammatory cytokines in an inflammatory environment. − However, the long-term use and dose escalation of MTX may cause mild (nausea, vomiting, rashes, stomatitis) and severe (hepatic, pulmonary, renal, and bone marrow abnormalities) side effects . These adverse effects are mainly due to their systemic distribution and accumulation in the non-target organs/tissues/cells/sub-cellular domains.…”

Section: Introductionmentioning

confidence: 99%

Ultrasound-Targeted Microbubble Destruction-Mediated Cell-Mimetic Nanodrugs for Treating Rheumatoid Arthritis

Guo

Wang

Huang

et al. 2023

ACS Biomater. Sci. Eng.

View full text Add to dashboard Cite

Rheumatoid arthritis (RA) is an autoimmune disease that mainly affects joints, and it can lead to disability and damage to vital organs if not diagnosed and treated in time. However, all current therapeutic agents for RA have limitations such as high dose, severe side effects, long-term use, and unsatisfactory therapeutic effects. The long-term use and dose escalation of methotrexate (MTX) may cause mild and severe side effects. To overcome the limitations, it is critical to target drug delivery to the inflamed joints. In this work, we constructed a folic acidtargeted and cell-mimetic nanodrug, MTX-loaded mesoporous silica composite nanoplatform (MMPRF), which can regulate drug release under ultrasound (US) and microbubble (MB) mediation. The targeted delivery and drug therapy were investigated through in vitro RAW264.7 cell experiments and in vivo collageninduced arthritis animal experiments. The result showed that the targeting ability to the joints of MMPRF was strong and was more significant after US and MB mediation, which can potently reduce joint swelling, bone erosion, and inflammation in joints. This work indicated that the US-and MB-mediated MMPRF not only would be a promising method for synergistic targeted treatment of RA but also may show high potential for serving as a nanomedicine for many other biomedical fields.

show abstract

Developments of microfluidics for orthopedic applications: A review

Cited by 8 publications

References 124 publications

Oxygen generating biomaterials at the forefront of regenerative medicine: advances in bone regeneration

Oxygen generating biomaterials at the forefront of regenerative medicine: advances in bone regeneration

Bone-on-a-Chip: Biomimetic Models Based on Microfluidic Technologies for Biomedical Applications

Ultrasound-Targeted Microbubble Destruction-Mediated Cell-Mimetic Nanodrugs for Treating Rheumatoid Arthritis

Contact Info

Product

Resources

About